Here’s what you should know.
1. The company expects results in the second quarter of fiscal year 2017.
2. Researchers conducted a randomized, double-blind, placebo-controlled study of Bekinda in patients with acute gastroenteritis and gastritis.
3. If the FDA approves Bekinda, it would be the first 5-HT3 antiemtetic drug designed for acute gastroenteritis and gastritis available in the United States.
4. RedHill is conducting a phase II study for its 12 mg version. The lower dose can treat diarrhea-predominant irritable bowel syndrome. RedHill expects to report results in mid-2017.
More articles on gastroenterology:
Takeda completes Ariad Pharmaceutical acquisition following NY law firm investigation — 3 GI companies making waves
GI leader to know: Dr. Shahab Aftahi of Estrella Gastroenterology
Versant Ventures launches Jecure Therapeutics: 4 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
